Reforms In China's Center For Drug Evaluation Designed To Boost Innovation - DIA China Conference
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Ongoing reforms in China's drug review body are attracting the attention of the pharma industry, which is hoping the changes will result in a faster drug review process. During the third annual DIA China meeting in Beijing, officials from China's Center for Drug Evaluation unveiled more details of the reform and reaffirmed that the ultimate goals are to improve quality and drive efficiency of drug reviews